Longevity Escape Velocity

What it proposes

If anti-aging interventions improve fast enough that they add more than one year of remaining life expectancy per chronological year, then a person alive at that moment could in principle continue to gain remaining life expectancy forever — never reaching the “end” of their lifespan.

This crossover threshold is “longevity escape velocity” (LEV). Aubrey de Grey popularised the term; Ray Kurzweil refers to a related “methuselarity”.

How plausible is it?

• Historical life expectancy has grown by ~3 months per year of progress in well-fed countries over the 20th century — well below the LEV threshold of 12 months per year, and that growth is now plateauing.
• The geroscience hypothesis would have to deliver intervention effects large enough to accelerate that rate dramatically.
• No proven mammalian intervention extends lifespan by anything close to what LEV would require for humans.

How to think about it

LEV is best understood as a possibility argument, not a prediction. It says: if certain technical milestones are reached, then this qualitative shift becomes possible. Whether the milestones will be reached in any given timeframe is open.

What it changes for the present

Even sceptics of literal LEV acknowledge a softer version: each decade, the level of intervention available to a person born today is likely better than what was available to people born ten years earlier. Staying healthier longer keeps you eligible to benefit from future interventions — an argument for healthspan-focused choices now regardless of where LEV ultimately lands.

Related entries

Aubrey de Grey, Healthspan vs lifespan, Geroscience hypothesis.